Study finds oral testosterone therapy undecanoate is effective, with no liver toxicity
WASHINGTON--An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with low testosterone levels, with no evidence of liver toxicity. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
TST is currently available in multiple modes of administration, including implantable pellets, transdermal gels and intramuscular injections.
"For many men with low testosterone levels, an oral option is preferred to avoid issues associated with other ...

